These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 1973252)
21. The potential impact of recombinant factor VIII on hemophilia care and the demand for blood and blood products. VanAken WG Transfus Med Rev; 1997 Jan; 11(1):6-14. PubMed ID: 9031486 [No Abstract] [Full Text] [Related]
22. [Advances in hemophilia treatment: a hepatitis-safe factor VIII concentrate]. Heimburger N Blut; 1982 Apr; 44(4):249-51. PubMed ID: 6805537 [No Abstract] [Full Text] [Related]
23. Non-A, non-B hepatitis after factor VIII concentrate treated by heating and chloroform. Mannucci PM; Colombo M; Rodeghiero F Lancet; 1985 Nov; 2(8462):1013. PubMed ID: 2865484 [No Abstract] [Full Text] [Related]
24. Heat-treated NHS factor VIII concentrate in the United Kingdom--a preliminary study. Colvin BT; Ainsworth M; Machin SJ; Mackie IJ; Smith JK; Winkelman L; Haddon ME Clin Lab Haematol; 1986; 8(2):85-92. PubMed ID: 3015481 [TBL] [Abstract][Full Text] [Related]
25. [The prevention of liver disease in the hemophilic child]. Carnelli V; Serafini I; Simoni L; Moroni GA; Giulotto P; Colombo M Pediatr Med Chir; 1983; 5(3):41-7. PubMed ID: 6417626 [TBL] [Abstract][Full Text] [Related]
26. [Improvement in anti-hemophilic preparations and its problems. 2. Inadequacy of the heat treatment of factor concentrates on the inactivation of non-A, non-B hepatitis virus]. Inagaki M; Osano M Rinsho Ketsueki; 1988 May; 29(5):635-9. PubMed ID: 3145994 [No Abstract] [Full Text] [Related]
27. [Viral hepatitis in hemophiliac patients treated with commercial concentrates of factors VIII and IX]. Miranda ML; Lissen E; Vinuesa M; Jiménez JM; García de Pesquera F; Leal M Med Clin (Barc); 1985 Apr; 84(13):516-9. PubMed ID: 3923278 [No Abstract] [Full Text] [Related]
28. UK: Hemophiliac wins access to recombinant factor VIII. Gold J Can HIV AIDS Policy Law Rev; 2003 Dec; 8(3):62. PubMed ID: 15108666 [TBL] [Abstract][Full Text] [Related]
29. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates. Parquet A; Boneu B; Bosser C; Cazenave JP; Dirat G; Gazengel G; Grunebaum L; Sultan Y; Verroust F; Wiesel ML Nouv Rev Fr Hematol (1978); 1988; 30(4):205-7. PubMed ID: 3143099 [TBL] [Abstract][Full Text] [Related]
30. Viral safety of plasma-derived factor VIII and IX concentrates. Ludlam CA Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532 [TBL] [Abstract][Full Text] [Related]
31. Transmission of hepatitis C virus infection associated with home infusion therapy for hemophilia. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 1997 Jul; 46(26):597-9. PubMed ID: 9221327 [TBL] [Abstract][Full Text] [Related]
32. Acute fulminant non-A, non-B hepatitis leading to chronic active hepatitis after treatment with cryoprecipitate. Lee CA; Kernoff PB; Karayiannis P; Thomas HC Gut; 1985 Jun; 26(6):639-41. PubMed ID: 3924749 [TBL] [Abstract][Full Text] [Related]
33. Non-A, non-B hepatitis and heat-treated factor VIII concentrates. Preston FE; Hay CR; Dewar MS; Greaves M; Triger DR Lancet; 1985 Jul; 2(8448):213. PubMed ID: 2862396 [No Abstract] [Full Text] [Related]
34. Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate. Berntorp E; Nilsson IM; Ljung R; Widell A Lancet; 1990 Jun; 335(8704):1531-2. PubMed ID: 1972463 [No Abstract] [Full Text] [Related]